ExpreS2ion Biotech Holding AB is planning an Initial Public Offering and listing on Nasdaq Stockholm First North
ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby announces on May 26th 2016 that the company is planning an Initial Public Offering during June 2016 with planned listing on Nasdaq Stockholm First North. Fully subscribed, this offering will provide revenues of 18 MSEK to ExpreS2ion.
ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through their wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of new vaccines and diagnostics for e.g. Malaria and Zika. Since founded in 2010, the subsidiary has used its patented ExpreS2 platform to produce more than 200 proteins in collaboration with research institutions and pharma companies, with an efficacy and success rate superior to competing technologies.
Planned Investor Meetings
In connection with the planned Initial Public Offering, ExpreS2ion will participate in below listed information meetings in order to explain about the activity of the company and future plans:
|Date and time||Event||Place||Registration|
|1 June, 07:45 a.m. – 17:20 p.m.||Sedermeradagen||Clarion Hotel Post Drottningtorget 10 Göteborg SWEDEN||Please register via www.sedermeradagen.se|
|8 June, 11:45 a.m. – 13:00 p.m.||Investor Lunch||Scandic Hotel Klara Slöjdgatan 7 Stockholm SWEDEN||Please register via firstname.lastname@example.org|
|13 June, 11:45 a.m. – 13:00 p.m.||Investor Lunch||Malmö Börshus Skeppsbron 2 Malmö SWEDEN||Please register via email@example.com|
For further information regarding the Investor Events please contact Sedermera Fondkommission.
Sedermera Fondkommission is the financial advisor for ExpreS2ion in connection with the planned Initial Public Offering and listing on Nasdaq Stockholm First North.
For further information about ExpreS2ion please contact:
Steen Klysner, CEO
Phone: +45 2062 9908
For further information about the Initial Public Offering and listing please contact:
Phone: +46 (0)431 – 47 17 00